HK1126689A1 - Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders - Google Patents

Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders

Info

Publication number
HK1126689A1
HK1126689A1 HK09105923.2A HK09105923A HK1126689A1 HK 1126689 A1 HK1126689 A1 HK 1126689A1 HK 09105923 A HK09105923 A HK 09105923A HK 1126689 A1 HK1126689 A1 HK 1126689A1
Authority
HK
Hong Kong
Prior art keywords
drug
preparation
treatment
patients suffering
human albumin
Prior art date
Application number
HK09105923.2A
Other languages
English (en)
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of HK1126689A1 publication Critical patent/HK1126689A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09105923.2A 2007-10-26 2009-07-02 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders HK1126689A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702831A ES2332846B1 (es) 2007-10-26 2007-10-26 Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.

Publications (1)

Publication Number Publication Date
HK1126689A1 true HK1126689A1 (en) 2009-09-11

Family

ID=40583637

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105923.2A HK1126689A1 (en) 2007-10-26 2009-07-02 Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders

Country Status (17)

Country Link
US (1) US7851446B2 (pt)
EP (1) EP2111868B1 (pt)
JP (1) JP5437619B2 (pt)
CN (1) CN101417123B (pt)
AR (1) AR068901A1 (pt)
AU (1) AU2008233025B8 (pt)
BR (1) BRPI0804623B8 (pt)
CA (1) CA2641830C (pt)
CL (1) CL2008003133A1 (pt)
ES (2) ES2332846B1 (pt)
HK (1) HK1126689A1 (pt)
MX (1) MX2008013635A (pt)
NZ (1) NZ572131A (pt)
PL (1) PL2111868T3 (pt)
PT (1) PT2111868E (pt)
RU (1) RU2414925C2 (pt)
UY (1) UY31418A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
JP7316931B2 (ja) * 2016-08-18 2023-07-28 アルカヘスト，インコーポレイテッド 加齢性認知障害の処置としての血漿画分
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
WO2020018343A1 (en) * 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3643319A1 (en) * 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
EP3870190A4 (en) 2018-10-26 2022-09-07 Alkahest, Inc. USE OF PLASMA AND PLASMA FRACTIONS TO REDUCE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY
JP2024516390A (ja) * 2021-04-30 2024-04-15 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 認知機能障害を処置するための治療的血漿交換及び低体積血漿交換の使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5112298A (en) 1990-06-25 1992-05-12 Baxter International Inc. Apheresis method and device
US5178603A (en) 1990-07-24 1993-01-12 Baxter International, Inc. Blood extraction and reinfusion flow control system and method
US6627151B1 (en) * 1997-06-13 2003-09-30 Helmut Borberg Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
ATE312354T1 (de) 2000-05-23 2005-12-15 Univ Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
EP1370240A4 (en) * 2001-03-02 2004-09-22 Neuron Therapeutics Inc NEUROPROTECTOR FORMULATIONS AND METHOD
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
KR101122782B1 (ko) 2002-10-04 2012-04-12 프라나 바이오테크놀로지 리미티드 신경 활성 화합물
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
UA80469C2 (en) 2003-02-13 2007-09-25 Octapharma Ag Method for the production of albumin
US20050042284A1 (en) 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US7436304B1 (en) 2005-07-19 2008-10-14 Visible Assets, Inc Evidence tracking

Also Published As

Publication number Publication date
NZ572131A (en) 2010-06-25
US20090111740A1 (en) 2009-04-30
JP2009108059A (ja) 2009-05-21
CN101417123B (zh) 2012-06-27
CL2008003133A1 (es) 2009-08-07
PT2111868E (pt) 2013-10-17
UY31418A1 (es) 2009-05-29
EP2111868A1 (en) 2009-10-28
EP2111868B1 (en) 2013-08-21
ES2332846A1 (es) 2010-02-12
JP5437619B2 (ja) 2014-03-12
AU2008233025B2 (en) 2013-06-27
CN101417123A (zh) 2009-04-29
CA2641830C (en) 2013-07-16
AU2008233025B8 (en) 2013-07-25
RU2414925C2 (ru) 2011-03-27
AU2008233025A1 (en) 2009-05-14
BRPI0804623B1 (pt) 2020-02-11
ES2428698T3 (es) 2013-11-08
BRPI0804623B8 (pt) 2021-05-25
AR068901A1 (es) 2009-12-16
US7851446B2 (en) 2010-12-14
PL2111868T3 (pl) 2014-01-31
MX2008013635A (es) 2009-05-11
RU2008141076A (ru) 2010-04-27
CA2641830A1 (en) 2009-04-26
BRPI0804623A2 (pt) 2009-06-30
ES2332846B1 (es) 2010-07-08

Similar Documents

Publication Publication Date Title
HK1126689A1 (en) Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
ZA200808758B (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
IL213407A (en) Use of combinations of drug factors to prepare combination therapy drugs
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
IL182105A0 (en) Use of memantine for the preparation of a medicament for the treatment of childhood behavioral disorders
HK1258028A1 (zh) 人類抗體及其在神經疾病治療中的診斷和治療用途
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EP1838316A4 (en) MACROCYCLIC ANALOGUES USEFUL FOR THE TREATMENT OF IMMUNOREGULATION DISORDERS AND RESPIRATORY DISEASES
IL206435A0 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
EP2203174A4 (en) THERAPEUTIC REGIMES FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
IL207977A0 (en) Therapy for disorders of the proximal digestive tract
HRP20040104A2 (en) Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
IL186916A0 (en) Use of insp052 polypeptide for the preparation of a medicament for treating diseases
GB0417474D0 (en) Treatment of respiratory disorders